Salute e Benessere

Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in…

CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S.New clinical data supporting use of Nanox.ARC to be presented at European Congress of Radiology (ECR) 2025.Nanox.ARC is an FDA, CE Marked, digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization.Nanox.ARC unlocks significant value for medical practices, providers, and their patients...

TOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy…

Advancing Dermatological Care Torsten BoveandTomasz Zawada, founders of TOOsonix, expressed enthusiasm for the partnership: "We are thrilled to join forces with MikronMed to make our focused ultrasound therapy more easily accessible for patients across the Nordic region. Our technology provides safe non-invasive treatment for a broad range of dermatological conditions, including skin cancers and pre-cancers, with improved efficiency and aesthetic outcomes compared to...

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further…

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights into potential enhanced treatment effects and durability of induced immune response The trial already yielded convincing one-year data and remains on track for two-year data readout in the second half of 2025COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S...

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

IND clearance for Jankistomig is on track for late 2025 IND clearance for Jankistomig is on track for late 2025 LONDONandBOSTON , Feb. 25, 2025 /PRNewswire/ -- Ottimo Pharma ("Ottimo"), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment ofRobert Tigheas Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo's...

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. This innovative approach works by reducing microglial activation, a key factor in the persistent brain...

Zymeworks Announces Participation in Upcoming Investor Conferences

TD Cowen 45 thAnnual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and present on March 4 at 10:30 am Eastern Time (ET) in Boston, MA.Leerink Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and present on March 10 at 8:00 am ET in Miami, FL.Barclays 27 thAnnual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on March 11 in Miami, FL.Jefferies Biotech on...

Contura Orthopedics Expands to Canada, Bringing Arthrosamid® to North America

Addressing the Growing Burden of Osteoarthritis Osteoarthritis is the most common form of arthritis, affecting millions worldwide and imposing a significant burden on healthcare systems.InCanada, approximately 4 million people [1] suffer from OA, with knee osteoarthritis being a leading cause of pain, mobility issues and reduced quality of life. As the population ages and obesity rates rise, the prevalence of OA continues to grow, increasing the demand for effective,...

Orion Corporation: The Board of Directors of Orion Corporation decided on…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 25 FEBRUARY 2025 at 12.35 EET Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company's key persons The Board of Directors of Orion Corporation has decided on new share-based incentive programs for the Group's key persons: a Long-term Incentive Program and a Restricted Share Unit Plan 2025–2027...

Notice to the Annual General Meeting of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING25 FEBRUARY 2025 at 12:15 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of the Annual General Meeting to be held on Thursday 3 April 2025 at 2:00 p.m. Finnish time at Messukeskus Siipi conference centre at the address Rautatieläisenkatu 3, Helsinki, Finland. The reception of attendees who have registered for the meeting and the distribution of...

ITM to Present Top Line Results from Phase 3 COMPETE Trial with…

Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM ) ,a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase 3 COMPETE trial in an oral presentation at the 22 ndAnnual European Neuroendocrine Tumor Society (ENETS) Conference 2025, held from March 5 – March 7, 2025 in Kraków, Poland. The COMPETE trial evaluated [ 177 Lu]Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted...

Orion Group Financial Statement Release January–December 2024

ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/202425 FEBRUARY 2025 at 12:00 EETOrion Group Financial Statement Release January–December 2024Net sales totalled EUR 1,542.4 (January–December 2023: 1,189.7) million Operating profit was EUR 416.6 (274.9) millionBasic earnings per share were EUR 2.35 (1.54)Cash flow from operating activities per share was EUR 2.09 (0.85)The Board of Directors proposes a dividend of EUR 1.64 (1.62) to be paid for 2024. The dividend is...

Illuccix® Prostate Cancer Imaging Agent Approved in Luxembourg

PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[5]. Illuccix® PSMA-PET will help fulfil a critical unmet need by…

PCI Biotech: Invitation to preliminary full-year 2024 results presentation

The presentation will be held as a live webcast available through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console.The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day.For further information, please contact: Ronny Skuggedal, CEO /...

Opdateret finanskalender 2025

Selskabsmeddelelse 2/2025 25. februar 2025 OPDATERET FINANSKALENDER Selskabet opdaterer hermed den finansielle kalender i forbindelse med offentliggørelsen af selskabets årsrapport for 2024 og generalforsamling, som udskydes til henholdsvis mandag den 31. marts 2025 og fredag den 25. april 2025 kl...

Year-end report: SciBase

The fourth quarter in figures The fourth quarter in figures January - December in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onFebruary 25, 2025. This interim report report has not been...

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of…

Study shows significant functional improvements after one year of ARC-EX TherapyImprovements were observed throughout one-year treatment period with no plateauResults demonstrate the importance of sustained access to ARC-EX TherapyEINDHOVEN, the Netherlands, Feb.25, 2025(GLOBE NEWSWIRE) --ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with...

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to…

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries.COPENHAGEN, Denmark, February 25, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic's chikungunya vaccine in low- and middle-income (LMIC) countries.Initially, the companies have entered into a contract manufacturing...

Press Release: Sarclisa approved in Japan for patients with newly diagnosed…

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myelomaParis, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan...

HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to…

Key Takeaways from the Human papillomavirus (HPV) 16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) Market Report Key Takeaways from the Human papillomavirus (HPV) 16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) Market Report Discover which therapies are expected to grab the major HPV16+ HNSCC market share @ HPV16-Positive Head and Neck Squamous Cell Carcinoma Market Report HPV16-Positive Head and Neck Squamous Cell Carcinoma Overview HPV16-positive head and...

Galapagos to Present at Upcoming Investor Conferences

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45 thAnnual Healthcare Conference Date: Tuesday, March 4, 2025 Location: Boston, MA Corporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CET Live Webcast Link:...

KSrelief Pledges USD 500 Million to Global Polio Eradication Effort, Marking…

The WHO partnership, with its USD 300 million investment, focuses on Pakistan and Afghanistan while strengthening national programs in countries nearing polio eradication, and will provide essential supplies and preventive programs to these high-risk areas. Complementing this effort, the UNICEF collaboration, backed by a USD 200 million budget, will support supply chains, including vaccine purchases and cold storage systems; it will also bolster primary healthcare centers and vaccination…

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Grünenthal acquired the global rights to Qutenza® in 2018 as part of its growth strategy. Since 2017, the company has invested more than €2 billion in successful M&A transactions and continues to generate additional value by integrating the acquired brands into Grünenthal's infrastructure, creating synergies throughout manufacturing, logistics, and commercial activities. Grünenthal acquired the global rights to Qutenza ®in 2018 as part of its growth strategy. Since 2017, the company has...

3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in…

"This study represents a major leap forward in our understanding of ADHD therapeutics," commented Dr. Karl Karlsson, CEO of 3Z Pharmaceuticals, emphasizing the study's significance, "By leveraging advanced metabolomics and lipidomics, we have uncovered a shared metabolic signature across treatments—highlighting the potential of L-type calcium channel modulation as the foundation for a new non-stimulant ADHD therapy. These findings not only validate our drug discovery platform but…

Artificial Limbs and Joints Market to Reach USD 4.5 Billion by 2031, Driven by…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1017504 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1017504 202 – Pages 126 – Tables 37 – Figures Scope Of The Report Artificial Limbs and Joints Market Overview Geographic Dominance : North Americadominates the Artificial Limbs and Joints Market due to its advanced healthcare infrastructure, high healthcare spending, and strong presence...

Altri Comunicati